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Abstract
The CAPOX/Bev (capecitabine plus oxaliplatin and bevacizumab) regimen has previously shown efficacy for
patients with metastatic colorectal cancer (mCRC). Data on the efficacy and safety of CAPOX/Bev, followed by
maintenance capecitabine and bevacizumab for elderly patients with mCRC, are limited. The present small
study has shown that CAPOX/Bev, followed by maintenance capecitabine and Bev is safe and effective for
mCRC patients aged > 75 years.
Background: The aim of the present study was to evaluate the efficacy and safety of the combination of CAPOX-Bev
(capecitabine [Cap] plus oxaliplatin and bevacizumab [Bev]), followed by maintenance Cap and Bev, for patients with
metastatic colorectal cancer (mCRC) and aged > 75 years. Patients and Methods: The regimen consisted of
intravenous oxaliplatin 130 to 100 mg/m2 on day 1, oral Cap 750 to 1000 mg/m2 twice daily on days 1 to 14, and Bev
7.5 mg/kg on day 1, every 3 weeks. After 4 cycles of CAPOX-Bev, the patients without evidence of disease pro-
gression received maintenance treatment with Cap 1000 to 1250 mg/m2 twice daily on days 1 to 14 and Bev 7.5 mg/kg
on day 1, every 3 weeks, until disease progression or unacceptable toxicity. The primary endpoint was the 9-month
disease control rate. Progression-free survival (PFS), overall survival (OS), and safety were the secondary endpoints.
Results: Overall, 36 patients were enrolled from March 2012 to April 2017 at our institution. After completion of
CAPOX/Bev, 15 patients (41.7%) had a partial response, 18 (50.0%) had stable disease, and 3 (8.3%) had progressive
disease. Thirty-three patients (91.7%) received the Cap/Bev regimen as maintenance treatment for a median of 8.6
cycles (range, 3-14 cycles). The 9-month DCR was 58.3% (95% confidence interval [CI], 40.8-74.5), the median PFS
was 8.8 months (95% CI, 6.7-10.3 months), and the median OS was 20.8 months (95% CI, 16.1-25.4 months). With
the CAPOX/Bev regimen, the most common grade 3 toxicity included neutropenia (11.1%), diarrhea (5.5%), nausea/
vomiting (2.8%), and fatigue (2.8%). Grade 3 neurotoxicity was not observed. With Cap/Bev maintenance therapy,
grade 3 hand-foot syndrome was observed in 2 patients (6.0%). Conclusion: CAPOX/Bev, followed by Cap/Bev as
maintenance treatment, is safe and effective in terms of PFS and OS for elderly patients aged > 75 years with mCRC.
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CAPOX/Bev and XELOX for mCRCIntroduction
Colorectal cancer (CRC) is the third most common malignancy
and the fourth leading cause of cancer mortality worldwide.1
More than one third of CRC diagnoses occur in patients
aged  75 years.2 Nevertheless, clinical trials designed to include
the elderly population are still limited, as is the evidence sup-
porting the treatment of advanced CRC for this specific
population.3
Despite surgical resection currently representing the only chance
of long-term cure, a variable proportion of patients develop recur-
rence or present at diagnosis with locally advanced or metastatic
CRC (mCRC) and thus are candidates for systemic chemotherapy.
Of the available chemotherapy agents, the fluoropyrimidines 5-
fluorouracil (5-FU) and capecitabine (Cap) are the most active
and conventionally administered drugs for mCRC.4 In the past,
large randomized trials demonstrated that oxaliplatin (L-OHP)
combined with 5-FU (FOLFOX) or Cap (CAPOX) and the anti-
angiogenic agent bevacizumab (Bev) significantly improved
progression-free survival (PFS) and overall survival (OS) for patients
with mCRC.5,6 In most analyses, FOLFOX or CAPOX, plus Bev
were administered for  12 or 8 cycles, respectively, or until
progressive disease or unacceptable toxicity developed. Grade 3/4
hematologic and nonhematologic adverse events occur frequently.
In particular, peripheral sensory neuropathy (PSN), a cumulative
dose-limiting toxicity of L-OHP, often requires drug discontinua-
tion before disease progression.5-7 Alternative treatment strategies,
such as “stop and go” or intermittent chemotherapy, have been
evaluated to minimize the severity of adverse events.8,9 A phase II
study led by our research group showed promising results in terms
of PFS and a very low incidence of grade 3 PSN for mCRC patients
treated with FOLFOX stop and go and Cap as maintenance
chemotherapy.10 In addition, the activity of FOLFOX or CAPOX,
plus Bev, followed by leucovorin/5-FU or CAP with Bev as main-
tenance treatment was reported in other recent studies.11,12 How-
ever, in most trials, the population included was aged < 75 years
and had a good performance status (PS), on average; hence, data
suggesting the most effective chemotherapy regimen for elderly and
vulnerable patients are limited. Older adults with mCRC often have
comorbidities that complicate the administration of aggressive
treatments; thus monochemotherapy or best supportive care alone
are often recommended for patients aged > 75 years. However,
elderly patients with a good PS and considered fit using a
comprehensive geriatric assessment might benefit from the admin-
istration of a multidrug treatment regimen.13
The present study evaluated the clinical efficacy and tolerability
of induction chemotherapy with CAPOX/Bev followed by Cap/Bev
as maintenance treatment in nonfrail patients aged > 75 years.
Patients and Methods
Eligibility Criteria
For the present prospective observational study, patients aged
> 75 years with histologically proven and radiologically measurable
mCRC were enrolled at our institution. No previous chemotherapy
for advanced disease was allowed. Adjuvant chemotherapy, if
administered, had to have been completed  6 months before
study entry. The other eligibility criteria included Eastern Coop-
erative Oncology Group PS of 0 to 2, a life expectancy of  3nical Colorectal Cancer Month 2018months, adequate hematologic parameters (absolute neutrophil
count,  1.5  109/L; platelet count,  100  109/L),
creatinine < 1.5 times the upper limit of the normal range, total
bilirubin < 3 times the upper normal limit, aspartate and alanine
aminotransferase < 3 times the upper normal limit, and the absence
of a second primary tumor other than nonmelanoma skin cancer or
in situ cervical carcinoma. The exclusion criteria were histologic
evidence of predominantly squamous cell cancer, a history of gross
hemoptysis ( 2.5 mL), brain metastases or previous treatment of
brain metastasis, uncontrolled pleural or pericardial effusion or as-
cites, pregnancy or lactation, a history of documented hemorrhagic
diathesis or coagulopathy, therapeutic anticoagulation, the regular
use of aspirin (> 325 mg/d), nonsteroidal anti-inflammatory agents
known to inhibit platelet function, radiation therapy within 21 days
before enrollment or major surgery within 28 days before enroll-
ment, clinically significant cardiovascular disease, and medically
uncontrolled hypertension.
Using a baseline geriatric assessment that included evaluation of
activities of daily living, instrumental activities of daily living, and
the Charlson score for comorbidities,14 the patients were classified
as fit, vulnerable, or frail. Specifically, subjects with activities of daily
living limitations and > 2 comorbidities were classified as frail and
were excluded from the present study.15 All the included patients
provided their written informed consent.
Patient Evaluation
Patients were seen at the start of every chemotherapy cycle for a
physical examination, monitoring of symptoms and toxic effects,
assessment of renal function, and a complete blood count. mCRC
was reassessed after completion of 4 cycles of CAPOX/Bev and
thereafter at 3-month intervals until evidence of disease progression
(PD). The objective tumor response was evaluated using the
Response Evaluation Criteria in Solid Tumors, version 1.1.
Treatment Delivery
Induction chemotherapy consisted of 4 cycles of intravenous
L-OHP 100 to 130 mg/m2 on day 1 plus oral Cap 750 to 1000
mg/m2 twice daily on days 1 to 14 and intravenous Bev 7.5 mg/kg
on day 1 every 3 weeks. Given the advanced age of our study
population, L-OHP and Cap were administered at a full-dose solely
to fit patients aged  80 years and at a reduced dose (100 mg/m2
for L-OHP and 750 mg/m2 twice daily for Cap) to vulnerable
patients and subjects aged > 80 years to minimize the occurrence of
L-OHPe and Cap-related adverse events. Maintenance treatment
consisted of Cap 1250 mg/m2 twice daily on days 1 to 14 (1000
mg/m2 twice daily for vulnerable patients) and Bev at a dose of
7.5 mg/kg.
Toxicity
Toxicity was assessed using the National Cancer Institute
Common Terminology Criteria for Adverse Events, version 4.02.
Treatment was delayed if, on the planned day of treatment, the
neutrophil count was < 1500/mm3, the platelet count
was < 100,000/mm3, or the patient had persistent diarrhea or
stomatitis of grade > 1. Any patient who required > 2 weeks for
recovery from adverse reactions was excluded from the present
study. In the event of grade 4 hematologic or any other severe
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Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group; PS ¼ performance status.
Roberto Petrioli et al(grade  3) organ toxicity, the chemotherapeutic drug doses were
reduced by 25% for subsequent courses.
Statistical Analysis
The primary endpoint was the 9-month disease control rate
(DCR), defined as the percentage of patients with stable disease
(SD) or partial (PR) or complete response within 9 months after the
start of induction treatment. Fluoropyrimidines can be considered
reference drugs for elderly patients with advanced CRC, and most
studies investigating these agents as monochemotherapy have sug-
gested that w20% of patients will still be progression free at 9
months after treatment onset.4 The hypothesis for the present study
was that using CAPOX/Bev as induction chemotherapy and Cap/
Bev as maintenance treatment  40% of patients would be
progression free 9 months after the start of chemotherapy. We
calculated that a total of 33 patients should be recruited to yield an
80% probability to correctly select the treatment when it was
superior by an absolute difference of 20% in the 9-month DCR
(Simon’s minimax design).16
The secondary endpoints included safety, PFS (calculated as the
time from the first chemotherapy infusion to PD, death from any
cause, or censored at the last follow-up visit, whichever came first), OS
(measured from the date of treatment start to the date of death or the
last follow-up visit), and the objective response rate (the proportion of
patients achieving a PR or complete response). The Kaplan-Meier
method was used to evaluate the distributions of PFS and OS,
including the median time-to-event and 95% confidence intervals
(CI). Statistical analyses were conducted using STATAiC software.
Results
Patient Characteristics
From March 2012 to April 2017, 36 patients with newly diag-
nosed mCRC who were aged > 75 years were enrolled in the
present study. The baseline demographic and clinical characteristics
of patients are presented in Table 1. Their median age was 79 years
(range, 76-87 years), and more than one third (13 of 36; 36.1%) of
the patients were aged > 80 years. The vast majority of patients (33
of 36; 91.7%) had an Eastern Cooperative Oncology Group PS of
0 or 1 and approximately two thirds (24 of 36; 66.7%) of the pa-
tients were classified as fit. Twenty-eight patients (77.7%) had
undergone previous surgery with curative intent and were offered
our treatment protocol after documentation of unresectable locally
advanced or metastatic disease. Sixteen patients (44.4%) had
previously received adjuvant chemotherapy. Twenty-six patients
(72.2%) had liver metastases. At baseline, all the patients had  1
comorbidity, and most (23 of 36; 63.9%) had > 1 (Table 2). The
most frequent concomitant illnesses were cardiovascular disease (16
of 36; 44.4%).
Efficacy
All 36 enrolled patients completed 4 cycles of induction chemo-
therapy and were evaluable for response and toxicity. The starting L-
OHP dose was 130mg/m2 for 17 fit patients aged 80 years and 100
mg/m2 for 12 vulnerable patients and 7 fit patients aged  80 years.
Of the 36 patients, 15 (41.7%) had a PR and 18 (50.0%) had SD as
the best response to therapy after initial CAPOX/Bev (Table 3). The
33 patients (91.7%) with a PR or SD after induction chemotherapywithCAPOX/Bev receivedmaintenance chemotherapy withCap and
Bev for a median of 8.6 cycles (range, 3-14 cycles). The objective
response rate for Cap/Bev maintenance treatment was 15%. Twenty-
seven patients discontinued maintenance chemotherapy because of
PD. For 7 of these patients, whowere fit and aged 80 years, L-OHP
was reintroduced. One patient was lost to follow-up 10 months after
the onset of induction chemotherapy. One patient was continuing
maintenance treatment at the last follow-up visit. The 9-month DCR
was 58.3% (95% CI, 40.8%-74.5%), and median PFS was 8.8
months (95% CI, 6.7-10.3 months). Finally, 21 patients (58.3%)Clinical Colorectal Cancer Month 2018 - 3
Table 2 Patient Comorbidities
Comorbidities Patients, n (%)
Cardiovascular 16 (44.4)
Hypertension 12 (33.3)
Coronary artery disease 5 (13.9)
Arrhythmia 4 (11.1)




> 1 Comorbidity 23 (63.9)
Figure 1 Progression-Free Survival (Solid Line) and Overall
Survival (Dashed Line) for 36 Enrolled Patients





Neutropenia 5 (15.1) 4 (11.1)
Anemia 4 (11.1) 1 (2.8)
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4 - Clireceived irinotecan-based chemotherapy as second-line treatment,
and 9 patients (25%) received regorafenib as third-line therapy.
At a median follow-up period of 31.5 months (range, 7.3-41.9
months), 28 patients had died, and the median OS was 20.8
months (95% CI, 16.1-26.4 months). The PFS and OS for the 36
enrolled patients are illustrated in Figure 1.
Treatment Toxicity
The toxicity occurring during the CAPOX/Bev induction
regimen is summarized in Table 4. Grade 3 adverse events included
neutropenia (11.1%), diarrhea (5.5%), nausea/vomiting (2.8%),
and fatigue (2.8%). Four patients (11.1%) required  1 L-OHP
and Cap dose reductions because of toxicity, and 13 cycles (9.0%)
were delayed for  1 week.
Toxicity during maintenance treatment was mild. Two patients
(6.0%) experienced grade 3 hand-foot syndrome, one (3.0%)
developed grade 3 diarrhea, one (3.0%) had grade 3 hypertension,
and one (3.0%) developed grade 3 venous thrombosis (Table 5). No
patient experienced grade 3 proteinuria or epistaxis. A dose reduc-
tion of Cap was required for 4 patients. Bev administration was
definitively interrupted for 1 patient aged 83 years 3 months after
the onset of maintenance treatment because of the occurrence of
cognitive impairment. The neurologic symptoms, after neurologic
examination and encephalic magnetic resonance imaging, was
attributed to prolonged exposure to Bev, and the patient completely
recovered w6 weeks after Bev discontinuation.Table 3 Results
Variable n (%)
Objective response
Complete response 0 (0)
Partial response 15 (41.6)
Stable disease 18 (50.0)
Progressive disease 3 (8.3)
9-mo DCR, % (95% CI) 58.3 (40.8-74.5)
PFS, mo (95% CI) 8.8 (6.7-10.3)
OS, mo (95% CI) 20.8 (16.1-25.4)
Abbreviations: CI ¼ confidence interval; DCR ¼ disease control rate; OS ¼ overall survival;
PFS ¼ progression-free survival.
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Although favorable results have been reported previously for the
addition of Bev to standard first-line chemotherapy for mCRC
patients, increased toxicity has also been observed in association
with this combination; thus, particular caution should be exercised
when using it for the treatment of elderly patients.17 A reasonable
approach for nonfrail patients aged > 75 years with mCRC seems to
be an initial short-term combination chemotherapy regimen, fol-
lowed by a fluoropyrimidine associated with a biologic agent as
maintenance therapy.18,19 To the best of our knowledge, theThrombocytopenia 5 (15.1) 0 (0)
Nonhematologic
Nausea 3 (8.3) 1 (2.8)
Vomiting 1 (2.8) 0 (0)
Fatigue 8 (22.2) 1 (2.8)
Stomatitis 3 (8.3) 0 (0)
Sensory neuropathy 9 (25.0) 0 (0)
Diarrhea 7 (19.4) 2 (5.5)
Constipation 8 (22.2) 1 (2.8)
Hypertension 6 (16.7) 0 (0)
Proteinuria 1 (2.8) 0 (0)
Epistaxis 0 (0) 0 (0)
Cognitive 0 (0) 0 (0)
No grade 4 events developed in any of the 36 patients.
Abbreviations: Bev ¼ bevacizumab; CAPEOX ¼ capecitabine, oxaliplatin.






Neutropenia 2 (6.0) 0 (0)
Anemia 2 (6.0) 0 (0)
Thrombocytopenia 1 (3.0) 0 (0)
Nausea/vomiting 1 (3.0) 0 (0)
Abdominal pain 3 (9.0) 0 (0)
Diarrhea 3 (9.0) 1 (3.0)
Hand-foot syndrome 3 (9.0) 2 (6.0)
Bev-associated
Hypertension 3 (9.0) 1 (3.0)
Proteinuria 2 (6.0) 0 (0)
Epistaxis 2 (6.0) 0 (0)
Cognitive 1 (6.0) 0 (0)
Venous thrombosis 2 (6.0) 1 (3.0)
Abbreviations: Bev ¼ bevacizumab; Cap ¼ capecitabine.
Roberto Petrioli et alpresent study is the first to suggest that CapOX/Bev for 4 cycles,
followed by Cap/Bev as maintenance treatment, is feasible and
active for mCRC patients aged > 75 years. Albeit with the limi-
tations of a small study, the 58.3% 9-month DCR, 8.8-month PFS,
and 20.8-month median OS compare well with the results
commonly reported with the most active combination chemo-
therapy regimens in younger populations.5,6 The results of the
present study are also in line with the best results previously
observed in patients aged > 65 years with mCRC receiving
CAPOX/Bev or FOLFOX/Bev.20,21 A recent study demonstrated a
74.4% DCR, 7.9-month PFS, and 20.1-month OS for elderly
patients with mCRC receiving Bev combined with modified
CAPOX for a maximum of 12 cycles.22 However, most of those
patients were aged < 75 years, but all our patients were aged  75
years. Thus, although the median OS of 20.8 months in the present
study might seem lower than expected, especially with the use of the
newer agents available for patients with mCRC, 36.1% of our
enrolled patients were aged > 80 years (5 were aged > 85 years),
and 38.9% of our patients had > 1 metastatic site, including 19.4%
of the patients with peritoneum involvement. In addition, the DCR
was only 38% with irinotecan-based chemotherapy as second-line
treatment, and only 4 of 13 patients with wild-type tumors could
receive anti-EGFR agents (7 had a primary right tumor). Finally,
regorafenib, which could be administered as third-line therapy for
only 9 patients owing to a poor PS, resulted in a median PFS of 4.3
months.
In addition, the findings of our analysis are similar to those re-
ported in recent studies that highlighted the role of oral fluo-
ropyrimidines combined with Bev as maintenance therapy after
initial induction combination chemotherapy.23,24 In particular, the
large randomized trial CAIRO 3 (Maintenance Treatment Versus
Observation After Induction in Advanced Colorectal Carcinoma)
reported a greater median PFS than that observed in the present
study (11.7 vs. 8.8 months, respectively) and similar median OS(21.6 vs. 20.8 months, respectively) for the CAP/Bev maintenance
group after 6 cycles of initial CAPOX/Bev. Although the CAIRO 3
trial included patients aged  81 years, the median age of the 279
subjects enrolled in the maintenance group was only 63 years.23
Furthermore, a recent randomized phase III study reported an
OR of 66.7, a PFS of 8.3 months, and an OS of 23.8 months for
mCRC patients treated with CAPOX plus Bev for 6 cycles, followed
by Cap/Bev as maintenance treatment. The median age of that
study population was 56 years and in our study, was 79 years.25
Compared with the present analysis, better results have been
recently reported for a group of 52 Japanese patients with mCRC
treated with a stop and go strategy of CAPOX and Bev for 6 cycles,
followed by Cap/Bev as maintenance (OR, 55.8; PFS, 12.4 months;
OS, 30.6 months). However, only a few patients were aged > 75
years, and the median age was 66 years. Moreover, grade 3 PSN was
observed in 2 patients (3.8%), probably resulting from the planned
reintroduction of L-OHP.26
Although favorable results with the combination of Bev and Cap
as maintenance therapy have also been reported previously,23,24 to
the best of our knowledge, our analysis is the first to enroll patients
aged > 75 years. Furthermore, other maintenance approaches have
been previously tested in mCRC. Bev alone used as maintenance
treatment after induction chemotherapy did not improve survival
compared with no treatment (observation; median OS, 21.7 vs.
22.0 months) in a recent randomized phase III trial.27 In contrast,
single-agent capecitabine might be considered an appropriate
maintenance treatment option after XELOX or FOLFOX induction
regimens for mCRC patients with acceptable toxicities.18 Capeci-
tabine alone as maintenance treatment resulted in longer median
OS in a group of 136 patients (25.6 months) compared with that
for the observation-only group (23.3 months). However, the result
was not statistically significant (P ¼ .2247). Furthermore, the me-
dian age of the Cap-treated cohort (56 years) was much lower than
that of our study population (79 years).18
Despite the advanced median age and potential frailty of our
study population, the treatment was well tolerated and no unex-
pected toxic effects developed in the present study. The starting
dose of L-OHP and Cap was for many patients lower than the
conventional starting dose of 130 mg/m2 and 2000 mg/m2,
respectively. However, such dose reductions were determined owing
to the high rates of patients classified as vulnerable (33.3%) or
presenting with > 1 concomitant comorbidities (63.9%) in our
analysis. Possibly also for this reason, grade 3 neutropenia occurred
in only 11.1% of patients, and the severity of nausea and vomiting
was mild during initial CAPOX/Bev. In contrast, PSN, which is
related to the cumulative L-OHP dose, developed in several patients
in the present study (grade 2 in 25%) but never reached grade 3.
This safety profile is similar to, or even better than, that usually
reported with conventional CAPOX or FOLFOX-4 combined with
Bev for younger patients and could be partly attributed to the
shorter exposure to L-OHP, the accurate selection of nonfrail pa-
tients, and the starting dose reductions of L-OHP and Cap. Thus,
although no consensus has yet been reached regarding the definition
of frailty status, we deemed that patient age < 85 years, the ability
to perform activities of daily living, < 3 concomitant comorbidities,
and no cognitive impairment were the factors that can best deter-
mine a nonfrail patient. A reasonable approach that could be appliedClinical Colorectal Cancer Month 2018 - 5
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tool such as the G8 questionnaire, which allows for a quick
distinction between fit and nonfit patients. Nonfit subjects could be
further evaluated using a comprehensive geriatric assessment, which
can discriminate vulnerable and frail patients.28,29
The toxicities associated with Cap/Bev during maintenance
treatment were consistent with the known adverse events associated
with these drugs, especially for long-term use, and were grade 1 to 2
in most cases. However, a good safety profile is often the main
advantage of a treatment strategy that includes maintenance treat-
ment after induction chemotherapy before PD. The proportion of
grade 3 Cap/Bev-related adverse events in the present study was
lower than that reported in the AVEX clinical trial [a study of
bevacizumab (Avastin) in combination with capecitabine (Xeloda)
in elderly patients with metastatic colorectal cancer], which evalu-
ated Cap/Bev versus Cap alone for patients aged > 70 years with
mCRC (hand-foot syndrome, 6% vs. 16%; diarrhea, 3% vs. 7%;
venous thromboembolic events, 3% vs. 8%, respectively).30 This
difference might have simply resulted from the small size of the
present study and/or better selection of the enrolled patients (in the
AVEX trial, patients were not considered fit for combination
chemotherapy). Finally, Bev was interrupted in 1 patient aged > 80
years owing to the development of cognitive impairment. Although
the findings from the present study and other reports suggest that
appropriately selected older patients can tolerate well the addition of
Bev to chemotherapy, caution should be observed for patients aged
> 80 years, who are commonly at risk of developing cognitive
decline, with consequent deterioration of their quality of life.31
The potential shortcomings of our study included the single-arm
design, relatively small sample size, and long study duration of 5
years. The latter was chiefly the consequence of the single-
institution experience that included only very elderly patients,
which clearly delayed recruitment. Although clinical trials are war-
ranted to confirm our results in a larger population, our data could
aid treatment decision making for nonfrail patients aged > 75 years
with mCRC.
Conclusion
The results of the present study suggest that CAPOX/Bev, fol-
lowed by Cap/Bev as maintenance treatment, is safe and active as
first-line treatment for nonfrail mCRC patients aged > 75 years and
can achieve encouraging results in PFS and OS.
Clinical Practice Points
 In the past, several studies showed the efficacy of FOLFOX or
CAPOX, plus Bev, induction chemotherapy, followed by 5-
fluorouracil/leucovorin or Cap/Bev as maintenance treatment,
for patients with mCRC.
 However, most studies included patients aged < 75 years with
good PS.
 Therefore, data on the efficacy and safety of this regimen for
elderly patients with mCRC are limited.
 Also, because patients aged > 75 years commonly present with
comorbidities, monochemotherapy or best supportive care have
typically been preferred.nical Colorectal Cancer Month 2018 In the present prospective observational study, we reported the
efficacy and tolerability of CAPOX/Bev as induction treatment,
followed by Cap/Bev as maintenance therapy, for 36 patients with
newly diagnosed mCRC aged> 75 years and screened as nonfrail.
 On completion of the CAPOX/Bev regimen, more than one
third of the patients had a PR, one half had SD, and only few
had developed disease progression.
 Nearly all patients received the Cap/Bev regimen as maintenance
treatment.
 The 9-month DCR, median PFS, and median OS compared
well with those observed in several studies evaluating similar
regimens for younger populations.
 During CAPOX/Bev regimen and Cap/Bev maintenance treat-
ment, grade 3 adverse events were not common, in particular,
grade 3 neurotoxicity was not observed.
 Therefore, CAPOX/Bev, followed by maintenance Cap/Bev, can
be safely proposed as first-line treatment for nonfrail patients
with mCRC aged > 75 years.Disclosure
The authors declare that they have no competing interests.References
1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global
patterns and trends in colorectal cancer incidence and mortality. Gut 2017; 66:
683-91.
2. Young PE, Womeldorph CM, Johnson EK, et al. Early detection of colorectal
cancer recurrence in patients undergoing surgery with curative intent: current
status and challenges. J Cancer 2014; 5:262-71.
3. SEER Cancer Statistics Review, 1975-2013, based on November 2015 SEER data
submission, posted to the SEER web site, April 2016. Bethesda, MD: National
Cancer Institute, Available at: https://seer.cancer.gov/csr/1975_2013/. Accessed
March 19, 2018.
4. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with
intravenous fluorouracil plus leucovorin in patients with metastatic colorectal
cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-106.
5. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with
oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:
a randomized phase III study. J Clin Oncol 2008; 26:2013-9.
6. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and
fluoropyrimidine regimens with or without bevacizumab as first-line treatment of
metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008; 26:3523-9.
7. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 30(4
Suppl 15):5-13.
8. Maindrault-Goebel F, Tournigand C, André T, et al. Oxaliplatin reintroduction in
patients previously treated with leucovorin, fluorouracil and oxaliplatin for meta-
static colorectal cancer. Ann Oncol 2004; 15:1210-4.
9. Wadhawan A, Stephens R, Adams R. Intermittent therapy in the palliative treat-
ment of metastatic colorectal cancer. Expert Rev Anticancer Ther 2009; 9:125-34.
10. Petrioli R, Paolelli L, Marsili S, et al. FOLFOX-4 stop and go and capecitabine
maintenance chemotherapy in the treatment of metastatic colorectal cancer.
Oncology 2006; 70:345-50.
11. Vaidyanathan G, Groman A, Wilding G, Fakih MG. Stop and go FOLFOX plus
bevacizumab chemotherapy in the first-line treatment of metastatic colorectal
cancer. Oncology 2010; 79:67-71.
12. Díaz-Rubio E, Gómez-España A, Massutí B, et al. Group for the treatment of
digestive tumors: first-line XELOX plus bevacizumab followed by XELOX plus
bevacizumab or single-agent bevacizumab as maintenance therapy in patients with
metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012;
17:15-25.
13. Pallis AG, Papamichael D, Audisio R, et al. EORTC Elderly Task Force experts’
opinion for the treatment of colon cancer in older patients. Cancer Treat Rev 2010;
36:83-90.
14. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds
information to Eastern Cooperative Oncology Group performance status in elderly
cancer patients: an Italian Group for Geriatric Oncology study. J Clin Oncol 2002;
20:494-502.
15. Balducci L, Extermann M. Management of cancer in the older person: a practical
approach. Oncologist 2000; 5:224-37.
Roberto Petrioli et al
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials
1989; 10:1-10.
17. Jain VK, Hawkes EA, Cunningham D. Integration of biologic agents with cyto-
toxic chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer 2011;
10:245-57.
18. Luo HY, Li YH, Wang W, et al. Single-agent capecitabine as maintenance therapy
after induction of XELOX (or FOLFOX) in first-line treatment of metastatic
colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol 2016;
27:1074-81.
19. Esin E, Yalcin S. Maintenance strategy in metastatic colorectal cancer: a systematic
review. Cancer Treat Rev 2016; 42:82-90.
20. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to
fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled
analysis of cohorts of older patients from two randomized clinical trials. J Clin
Oncol 2009; 27:199-205.
21. Kozloff MF, Berlin J, Flynn PJ, et al. Clinical outcomes in elderly patients with
metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from
the BRiTE observational cohort study. Oncology 2010; 78:329-39.
22. Vamvakas L, Matikas A, Karampeazis A, et al. Capecitabine in combination with
oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable
elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a
multicenter phase II study of the Hellenic Oncology Research Group (HORG).
BMC Cancer 2014; 14:277.
23. Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with cape-
citabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3
randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015;
385:1843-52.24. Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance strategies
after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with
metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label,
phase 3 trial. Lancet Oncol 2015; 16:1355-69.
25. Yalcin S, Uslu R, Dane F, et al. Bevacizumab þ capecitabine as maintenance
therapy after initial bevacizumab þ XELOX treatment in previously untreated
patients with metastatic colorectal cancer: phase III “stop and go” study results—a
Turkish Oncology Group Trial. Oncology 2013; 85:328-35.
26. Nakayama G, Ishigure K, Yokoyama H, et al. The efficacy and safety of CapeOX
plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance
therapy in patients with metastatic colorectal cancer: a multi-center, single-arm,
phase II study (CCOG-0902). BMC Cancer 2017; 17:243.
27. Aparicio T, Ghiringhelli F, Boige V, et al. Bevacizumab maintenance versus no
maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a
randomized phase III trial (PRODIGE 9). J Clin Oncol 2018; 36:674-81.
28. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology
consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014;
32:2595-603.
29. Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer
patients: the ONCODAGE prospective multicenter cohort study. PLoS One 2014;
9:e115060.
30. Cunningham D, Lang I, Marcuello E, et al, AVEX Study Investigators. Bev-
acizumab plus capecitabine versus capecitabine alone in elderly patients with
previously untreated metastatic colorectal cancer (AVEX): an open-label, rando-
mised phase 3 trial. Lancet Oncol 2013; 14:1077-85.
31. Mohile SG, Magnuson A. Comprehensive geriatric assessment in oncology.
Interdiscip Top Gerontol 2013; 38:85-103.Clinical Colorectal Cancer Month 2018 - 7
